| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/06/2010 | US7749973 Defective lentivirus pseudotyped with a lyssavirus envelope; selective transfer of genes into astrocytes of central nervous system; nervous system and brain disorders; viral diseases |
| 07/06/2010 | US7749972 having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity or the like |
| 07/06/2010 | US7749971 Such as Hurler syndrome and Batten by administering an aminoglycosidesuch as gentamicin, G418, hygromycin B, paromomycin, tobramycin, lividomycin A, amikacin, sisomycin, or neomycin, optionally in combination with an enzyme effective for enzyme replacement therapy, a polyionic compound or gene therapy |
| 07/06/2010 | US7749970 Application of an azalide antibiotic such as azithromycin |
| 07/06/2010 | US7749962 administering to mammal with breast cancer as adjuvant therapy an agent effective in blocking interaction of integrin with extracellular matrix protein of bone marrow microenvironment or that downregulates expression of integrin; integrin is alpha 5 beta 1 and extracellular matrix protein is fibronectin |
| 07/06/2010 | US7749953 comprising regulating the expression or activity of cannabinoid receptors in bone cells |
| 07/06/2010 | US7749718 Method for raising or isolating an antibody to DCRS5 |
| 07/06/2010 | US7749548 Composite for the improvement of the smell of the armpit |
| 07/06/2010 | US7749547 Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise |
| 07/06/2010 | US7749543 Methods useful in the treatment of bone resorption diseases |
| 07/06/2010 | US7749542 For preventing oral abuse of an oral opioid formulation; provides a negative, "aversive" experience when a large amount of the opioid, e.g., about 2-3 times the usually prescribed dose, is taken by or administered to a physically dependent subject |
| 07/06/2010 | US7749540 Compositions comprising modafinil compounds |
| 07/06/2010 | US7749537 Pre-blending a drug susceptible to tackiness such as ibuprofen with an additive such as silica; directly compressing the blend without the need for a granulation step or roller compression |
| 07/06/2010 | US7749532 doxycycline; dosage forms have immediate release and delayed release portions; antiinflammatory, antiarthritic, and antidiabetic agents, periodontal disease, rosacea, acne, dry eyes, hyperparathyroidism |
| 07/06/2010 | US7749530 ocular implant comprising a tyrosine kinase inhibitor and a polymer matrix; 2,5-dimethyl-2H-pyrazole-3-carboxylic acid (3-{2-oxo-3-[(4-pyrrolidin-1-ylmethyl-phenylamino)-methylene]-2,3-dihydro-1H-indole-6-carbonyl}-phenyl)-amide and polylactide |
| 07/06/2010 | US7749529 inhibiting infection in an indwelling catheter defining at least one lumen therethrough by infusing an aqueous catheter lock solution into a lumen of the catheter, the solution comprising citrate, methylene blue and a paraben dispersed or dissolved therein |
| 07/06/2010 | US7749522 Organ arrest, protection and preservation |
| 07/06/2010 | US7749503 3-deoxyglucosone and skin |
| 07/06/2010 | US7749489 Topical administration carrier composition and therapeutic formulations comprising same |
| 07/06/2010 | US7749488 Topical drug delivery of an aerosol foam containing benzoyl peroxide, clindamycin or salt or ester, water, surfactant, buffer, xanthan gum, emollient and propellant; non-runny, easy to apply, and uses a low residue vehicle; quick-breaking foam |
| 07/06/2010 | US7749263 Poly(ester amide) filler blends for modulation of coating properties |
| 07/06/2010 | US7749253 Spine distraction implant and method |
| 07/06/2010 | US7748388 Endoscopic injectable preparation |
| 07/06/2010 | CA2587792C Therapeutic compositions for intranasal administration of ketorolac |
| 07/06/2010 | CA2563693C Composition and method of decreasing renal ischemic damage |
| 07/06/2010 | CA2539814C Isoquinolinone potassium channel inhibitors |
| 07/06/2010 | CA2539479C Isoquinoline potassium channel inhibitors |
| 07/06/2010 | CA2522761C Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 07/06/2010 | CA2502568C Novel trans-lutein enriched xanthophyll ester concentrate and a process for its preparation |
| 07/06/2010 | CA2484664C Green porphyrin loaded nanoparticles and their use in photodynamic therapy |
| 07/06/2010 | CA2459719C Pharmaceutical composition comprising gamma-butyrobetaine |
| 07/06/2010 | CA2454863C Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 07/06/2010 | CA2446149C Vitamin d analogues |
| 07/06/2010 | CA2437109C Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity |
| 07/06/2010 | CA2427429C Acylaminoalkyl-substituted benzenesulfonamide derivatives,their preparation, their use and pharmaceutical preparations comprising them |
| 07/06/2010 | CA2415962C Valsartan salts |
| 07/06/2010 | CA2393883C Salicylamide derivatives |
| 07/06/2010 | CA2382129C Novel derivatives of flavones, xanthones and coumarins |
| 07/06/2010 | CA2369393C High purity (1r,2s,4r)-(-)-2-[(2'-{n,n-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds as well as medicaments containing 1 or more of these compounds and their use |
| 07/06/2010 | CA2367548C Composition containing a precursor capable of being hydrolysed by gluco erebrosidase |
| 07/06/2010 | CA2365844C Texture masked particles containing an active ingredient |
| 07/06/2010 | CA2359462C Pyrazole compounds and uses thereof |
| 07/06/2010 | CA2335566C Effervescent drug delivery system for oral administration |
| 07/06/2010 | CA2333188C Multiparticulate pharmaceutical form with programmed and timed release and preparation method |
| 07/06/2010 | CA2318326C Novel pentasaccharides, processes for their preparation and pharmaceutical compositions containing them |
| 07/06/2010 | CA2295572C Treatment of inflammatory disorders of the bowel and urinary bladder |
| 07/06/2010 | CA2288059C Method of treating malignancies |
| 07/06/2010 | CA2286396C Oligonucleotides for enhanced bioavailability |
| 07/06/2010 | CA2286091C Polymer-platinum compounds |
| 07/06/2010 | CA2218028C Brain edema inhibitor |
| 07/06/2010 | CA2209360C Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen |
| 07/06/2010 | CA2177858C Benzimidazole derivatives, their preparation and their therapeutic use |
| 07/06/2010 | CA2150785C Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| 07/01/2010 | WO2010075561A1 Small molecule inhibitors of necroptosis |
| 07/01/2010 | WO2010075558A2 Compositions and methods for inhibition of the jak pathway |
| 07/01/2010 | WO2010075554A1 Synthesis of purine nucleosides |
| 07/01/2010 | WO2010075549A2 Nucleoside phosphoramidates |
| 07/01/2010 | WO2010075542A1 Cdk inhibitors |
| 07/01/2010 | WO2010075537A1 Formulations comprising vitamin d or derivatives thereof |
| 07/01/2010 | WO2010075521A1 Compositions and methods of treating cancer |
| 07/01/2010 | WO2010075469A1 Corydaline derivatives useful for reducing lipid levels |
| 07/01/2010 | WO2010075465A1 Compositions for drug administration |
| 07/01/2010 | WO2010075444A2 Nasal formulations of metoclopramide |
| 07/01/2010 | WO2010075443A1 Selective inhibitors of akt and methods of using same |
| 07/01/2010 | WO2010075423A2 Dendrimer based modular platforms |
| 07/01/2010 | WO2010075418A2 Glyceollins suppress androgen-responsive prostate cancer |
| 07/01/2010 | WO2010075417A1 Survivin specific t cell receptor for treating cancer |
| 07/01/2010 | WO2010075380A1 Anti-viral compounds |
| 07/01/2010 | WO2010075376A2 Anti-viral compounds |
| 07/01/2010 | WO2010075372A1 Inhibitors of mre11, rad50 and/or nbs1 |
| 07/01/2010 | WO2010075353A1 Compositions useful for treating disorders related to trpa1 |
| 07/01/2010 | WO2010075347A2 Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
| 07/01/2010 | WO2010075332A1 Small molecule ligands of the integrin rgd recognition site and methods of use |
| 07/01/2010 | WO2010075315A2 Topical formulations of flap inhibitors for administration to an eye |
| 07/01/2010 | WO2010075314A2 Topical formulations of flap inhibitors for the treatment of dermatological conditions |
| 07/01/2010 | WO2010075301A1 Compositions comprising decitabine and tetrahydrouridine and uses thereof |
| 07/01/2010 | WO2010075290A1 Unsaturated heterocyclic inhibitors of necroptosis |
| 07/01/2010 | WO2010075287A2 Compounds and methods for the treatment of pain and other diseases |
| 07/01/2010 | WO2010075286A1 MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY |
| 07/01/2010 | WO2010075282A1 Molecular inhibitors of the wnt/beta-catenin pathway |
| 07/01/2010 | WO2010075280A2 Coumarin-based compounds |
| 07/01/2010 | WO2010075275A1 Selective release of non-racemic mixtures of two enantiomers from tablets and capsules |
| 07/01/2010 | WO2010075273A1 Bicyclic heterocycle derivatives and methods of use thereof |
| 07/01/2010 | WO2010075271A1 Bicyclic heterocycle derivatives and methods of use thereof |
| 07/01/2010 | WO2010075270A1 4, 6-disubstituted 2-amino-pyrimidines as histamine h4 receptor modulators |
| 07/01/2010 | WO2010075269A1 Pyrimidine derivatives as gpcr modttlators for use in the treatment of obesity and diabetes |
| 07/01/2010 | WO2010075266A2 Safe desmopressin administration |
| 07/01/2010 | WO2010075263A2 Compounds and methods for enhancing erythropoiesis |
| 07/01/2010 | WO2010075255A2 Methods for treating or preventing cancer and neurodegenerative diseases |
| 07/01/2010 | WO2010075239A1 Dosage regimen for a s1p receptor agonist |
| 07/01/2010 | WO2010075217A1 Methods of step-down hormone treatment |
| 07/01/2010 | WO2010075204A2 Gamma secretase modulators |
| 07/01/2010 | WO2010075203A1 Gamma secretase modulators |
| 07/01/2010 | WO2010075200A1 7-phenoxychroman carboxylic acid derivatives |
| 07/01/2010 | WO2010075197A1 Kinase inhibitors |
| 07/01/2010 | WO2010075175A1 Mass spectrometry assay for estrogenic compounds |
| 07/01/2010 | WO2010075127A1 Antiviral compounds |
| 07/01/2010 | WO2010075101A2 Treating picornavirus infection by targeting microrna mir-141 |
| 07/01/2010 | WO2010075090A2 Scopine modulators of muscarinic acetylcholine receptor |
| 07/01/2010 | WO2010075086A2 Pyrrolidinone inhibitors of pde-4 |